You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Request a contact

Stay informed

Live Chat

Introducing TRIUMEQ

Introducing TRIUMEQ

Triumeq - the first single-pill regimen built with DOLUTEGRAVIR at the core.5 Watch a visual exploration of DOLUTEGRAVIR and its structure-function relationship.

Watch Video

Statistically Superior Efficacy

DOLUTEGRAVIR – the only INI with statistically superior efficacy vs 3 core agent comparators in treatment-naïve patients. [1-3]

Learn more

High Barrier to Resistance

DOLUTEGRAVIR – an INI with a high barrier to resistance[1-5]

Learn more

Booster-Free Dosing

DOLUTEGRAVIR – sustained efficacy and a high barrier to resistance without the need to boost[5]

 

Learn more

Meet The Expert Webinars

Meet The Expert Webinars

A series of recorded webinars discussing a number of topical themes related to the management of HIV in general and/or the most recent clinical data supporting DOLUTEGRAVIR.

Watch Webinars

Data & Resources

Get access to electronic reprints of the key clinical data supporting Triumeq and additional resources for Healthcare Professionals

Access

 

Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg.

Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patient known to carry the HLA-B*5701 allele.[5]

References:

  1. Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naïve patients: week 96 and week 144 results from the SINGLE randomised clinical trial. J Acquir Immune Defic Syndr. 2015;70:515-519
  2. Molina J-M, Clotet B, van Lunzen J, et al; on behalf of the FLAMINGO Study Team. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naïve adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2(4):e127-e136.
  3. Orrell C, Hagins D, Belonosova E, et al. Superior efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) compared with ritonavir (RTV) boosted atazanavir (ATV) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naïve women with HIV-1 infection (ARIA Study). Presented at: Annual International AIDS Conference 2016; July 18-22, 2016. Durban, South Africa. Abstract THAB0205LB
  4. Raffi F, Jaeger H, Quiros-Roldan E, et al; on behalf of the extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11): 927-935.
  5. Triumeq SPC, GlaxoSmithKline 2016.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Tivicay & Triumeq is registered trademark of the GlaxoSmithKline Group of Companies